文献速递白血病

继发于乳腺癌的女性治疗相关急性淋巴细胞白血病

Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
PubMed 文献 · Br J Haematol · 2024-03-31

本文回顾性分析了37例乳腺癌治疗后确诊急性淋巴细胞白血病(ALL)的女性患者,重点进行细胞遗传学分类。费城染色体阳性(Ph+)、KMT2A重排和其他细胞遗传学改变分别占32%、22%和46%。中位总生存期(OS)和无复发生存期(RFS)分别为19.4个月和12.9个月。

要点

  • Ph+是乳腺癌治疗后治疗相关ALL最常见的细胞遗传学亚型,占32%。
  • Ph+患者OS和RFS均优于KMT2A重排和其他细胞遗传学组。
  • CR1期接受异基因造血干细胞移植(alloHCT)者中,KMT2A重排组OS和RFS更优。

核心结论

  • Ph染色体是乳腺癌治疗后治疗相关ALL最大的遗传学实体,可能与更优的生存结局相关;KMT2A重排可能与更差结局相关,或许可通过alloHSCT减轻。

研究设计与样本

  • 回顾性分析37例乳腺癌治疗后确诊ALL的女性患者,重点进行细胞遗传学分类。

主要发现

  • Ph+、KMT2A重排和其他细胞遗传学改变分别占32%、22%和46%。
  • 全体患者中位OS为19.4个月,中位RFS为12.9个月。
  • Ph+患者的OS和RFS分别优于KMT2A重排组和其他细胞遗传学组。
  • 17例(45.9%)患者在CR1期接受巩固性alloHCT,其中4例(24%)移植后复发。
  • 接受alloHCT后,KMT2A重排组的OS和RFS均更优。

关键数值与推荐

  • Ph+占32%,KMT2A重排占22%,其他细胞遗传学改变占46%。
  • 中位OS为19.4个月,中位RFS为12.9个月。
  • 17例(45.9%)在CR1期接受alloHCT,其中4例(24%)移植后复发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapy-related acute lymphoblastic leukaemia (tr-ALL) is a disease entity attributed to previous exposure to chemotherapy and/or radiation for antecedent malignancy. There is observed female predominance for tr-ALL, likely due to high prevalence and excellent curable rate for non-metastatic breast cancer as well as the frequent use of carcinogenic agents as part of adjuvant therapy. Here, we reviewed 37 women with diagnosis of ALL following breast cancer treatment with focus on cytogenetic categorization. Philadelphia chromosome positivity (Ph+), KMT2A alterations and other cytogenetic change groups were observed in 32%, 22% and 46% of patients respectively. Median overall survival (OS) and relapse-free survival (RFS) were 19.4 and 12.9 months, overall while both OS and RFS were superior in tr-ALL with Ph+ disease compared to KMT2Ar and other cytogenetics respectively. Seventeen (45.9%) patients underwent consolidative allogeneic haematopoietic cell transplantation (alloHCT) in CR1 out of which 4 (24%) relapsed following transplant. Both OS and RFS were superior in the KMT2Ar cytogenetics group following alloHCT. Ph chromosome represents the largest genetic entity of tr-ALL following breast cancer therapy, and it may be associated with superior survival outcomes while KMT2Ar may be associated with poorer outcomes that can perhaps be mitigated by alloHSCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Pourhassan H, Zhang J, Tinajero J, et al. Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer. Br J Haematol. 2024. PMID: 38556836. doi:10.1111/bjh.19432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。